Leronlimab Approval Status
FDA Approved: No
Generic name: leronlimab
Company: CytoDyn Inc.
Leronlimab is an investigational CCR5 antagonist in development for the treatment of HIV infection, metastatic triple-negative breast cancer, and severe respiratory complications associated with COVID-19.
- It was reported March 27, 2020 that leronlimab had been given to seven critically ill COVID-19 (coronavirus) patients in the New York area. Two of the seven patients recovered to a point that they were taken off ventilators, and another two are showing signs that their severe lung inflammation is subsiding.
- Leronlimab is thought to calm the aggressive immune response called the ‘cytokine storm’ that occurs in severely ill COVID-19 patients.
- Leronlimab has been granted Emergency Investigational New Drug (EIND) status by the FDA for use in COVID-19 patients.
- Leronlimab has been granted Fast Track Designation by the FDA for use as a combination therapy with HAART for HIV-infected patients, and as a treatment of patients with CCR5-positive metastatic triple-negative breast cancer (mTNBC).
- From early clinical trials studying leronlimab in the treatment of HIV, it is thought that possible side effects may include diarrhea, headache, swollen lymph nodes, high blood pressure, and injection site reactions.
Development Status and FDA Approval Process for leronlimab
|Jun 11, 2020||CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH|
|May 7, 2020||Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 Patients|
|May 4, 2020||FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May|
|Apr 30, 2020||CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries|
|Apr 27, 2020||CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients|
|Apr 15, 2020||First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19|
|Apr 7, 2020||CytoDyn Collaborating with U.K.’s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients|
|Apr 6, 2020||First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated|
|Apr 2, 2020||Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients|
|Mar 30, 2020||Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients|
|Mar 27, 2020||Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation|
|Mar 23, 2020||Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s Leronlimab, Bringing the Total to Four Patients|
|Mar 19, 2020||U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s Leronlimab|
|Mar 9, 2020||CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)|
|Mar 4, 2020||CytoDyn Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol|
|Jan 31, 2020||CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition|
|Jan 28, 2020||Leronlimab Under Evaluation for Potential Treatment of Coronavirus|
|Jan 22, 2020||Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC|
|Jan 13, 2020||CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer|
|Dec 17, 2019||CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV|
|Dec 3, 2019||CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial of Leronlimab|
|Nov 21, 2019||CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model|
|Nov 19, 2019||CytoDyn's Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies|
|Nov 12, 2019||CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer|
|Oct 1, 2019||CytoDyn Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH|
|Sep 27, 2019||CytoDyn Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naïve, Metastatic Triple-Negative Breast Cancer|
|May 8, 2019||CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals|
|May 7, 2019||FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.